Combination Trials: Companies Can Play Well in One Sandbox
In the AD field, most readers can count on one hand the companies that are widely known to have at least two drugs in sufficiently advanced stages to test combinations...
307 RESULTS
Sort By:
In the AD field, most readers can count on one hand the companies that are widely known to have at least two drugs in sufficiently advanced stages to test combinations...
Just days after the first report of a highly eccentric translation mechanism in the major genetic forms of ALS and FTLD comes a second paper showing the same phenomenon...
White blood cells age quickly in post-menopausal women who carry the ApoE4 gene, but estrogen slows that decline...
Alzheimer's disease clinicians who have read the FDA's draft guidance on developing drug combinations consider it too vague to design trials with it...
Research suggests that deep-brain stimulation (DBS) can help at earlier stages—before motor complications get out of control...
Over the past year, chatter has been building about combination drug therapy as the "New New Thing" in Alzheimer’s disease research...
Keystone Symposia Meeting, Part 1—Alzheimer’s Disease: Genes, Cellular Pathways and Therapies Keystone Symposia Meeting, Part 2—Genetics and Epidemiology of AD Keystone Symposia Meeting, Part 3—Amyloid Precursor Protein Function Keystone Symposia Meeting,